VN/12-1 is a novel retinoic acid metabolism blocking agent (RAMBA) discovered in our laboratory. The purpose of the study was to elucidate the molecular mechanism of VN/12-1's anticancer activity in breast cancer cell lines and in tumor xenografts. We investigated the effects of VN/12-1 on induction of autophagy and apoptosis in SKBR-3 cells. Further, we also 
Introduction
Breast cancer is the most common neoplasia in women. Despite significant advances in treatment, breast cancer remains incurable due to emergence of alternative pathways adopted by cancer cells to overcome the effects of anti-cancer therapy. To overcome this issue, a rational approach would be to concomitantly target clinically relevant cellular abnormalities with combination therapy or to use a potent multi-targeted agent. Mounting evidence indicates that the anti-tumor effects of all-trans retinoic acid (ATRA) are attributed to its ability to interfere with multiple facets of oncogenic signaling pathways (1, 2). Moreover, ATRA proved to be an effective anticancer agent to treat hematological cancers (3) . However, several factors compromise the widespread clinical use of ATRA. They include low in vitro anticancer potency, limited bioavailability and unfavorable pharmacokinetic behaviors due to rapid metabolism by CYP26 enzymes (4, 5) . Consequently, the structural modification of ATRA to develop novel retinoic acid metabolism blocking agents (RAMBAs) with improved potency and metabolic stability has been the focus of our group for many years. Our RAMBAs are considered to be atypical, because in addition to being potent inhibitors of ATRA metabolism, they also possess potent intrinsic multiple anti-cancer activities.
4-(±)-(1H-imidazol-1-yl)-(E)-retinoic acid (VN/14-1) and its corresponding methyl ester, VN/12-1 ( Figure 1A and Supplementary Figure S1 ) are amongst our lead RAMBAs (6) .
Previously, we had reported that flow cytometric analysis of breast cancer cells treated with our RAMBAs revealed significant growth arrest with only weak apoptosis (7), a phenomenon also reported for a variety of retinoids (8) . In an effort to search for strategies that could enhance cancer apoptosis mediated by RAMBAs, we looked for possible pro-survival pathways that may be activated in response to RAMBAs. VN/12-1 does not bind to or transactivate retinoic acid receptors (RARs) (7) and its exact molecular target (other than CYP26 inhibition) is yet to be identified. Herein, we report the induction of pronounced autophagy by VN/12-1-treated SKBR-3 cells and tumors.
Autophagy is an intracellular process in which proteins and cytoplasmic organelles are degraded (9) . It has been implicated in various physiological processes such as survival in stress, response to starvation and pathogenesis (10, 11) and a mechanism of cell protection against drug-induced apoptosis (12) (13) (14) . It is now generally accepted (15) that the accumulation of misfolded proteins in the lumen of the endoplasmic reticulum (ER) results in cellular stress that initiates a specialized response, designated ER stress response (ERS). In most cases, induction of cellular ERS subsequently leads to activation of autophagy (16, 17) .
While the estrogen receptor-alpha (ER-α) proficient breast tumors respond to several therapies, ER-α deficient tumors are less sensitive partly due to activation of growth factor signaling pathways such as human epidermal growth factor receptor-2 (Her-2) (18). Therefore, there is an urgent need for development of effective therapy against this type of breast cancer. In this study, we primarily focused on an ER-α deficient cell line which overexpresses Her-2 (SKBR-3 cells). We note that SKBR-3 xenograft model is one of the less commonly investigated model because of reported difficulty of SKBR-3 cells to form tumors in nude mice (19) .
However, a few research groups have previously successfully used this xenograft model in SCID mice (20, 21) .
The current study evaluated the potency and anti-tumor activity of VN/12-1, as a single agent and in combination chloroquine (CHL) ( Figure 1A ) (15) , an autophagy inhibitor that blocks lysosome acidification and autophagosome degradation. We show that VN/12-1 has dual effects on the cancer cells based on the dose. Low dose (< 10 μM) of VN/12-1 induces autophagy, ERS and cell cycle arrest as an immediate protective response in SKBR-3 cells and xenograft tumors. Importantly, we demonstrate that inhibition of autophagy using either pharmacological inhibitors (e.g. CHL) or RNA interference of essential autophagy gene Beclin-1 potentiates apoptotic cell death induced by VN/12-1. Notably, VN/12-1 produced impressive tumor inhibitory effects when used alone or in combination with CHL (p < 0.001).
Methods and Materials
Cell culture, cell growth inhibition, western blot, Annexin FITC, electron and immunofluorescence microscopy, siRNA, statistical analysis, in vivo studies See Figure   S1 ) (22) and 3-methyl adenine (3-MA) (23) were synthesized in our laboratory. Chloroquine (15) was purchased from Sigma Aldrich.
Supplementary Information Materials and Methods

Chemicals
Cell growth inhibition (MTT colorimetric assay):MTT (Sigma Aldrich) assay was performed as previously described (24) .
Cell cycle analysis:
Cell cycle analysis was performed using method a previously described method (24) .
In vivo tumor growth
All animal studies were performed according to the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of Thomas Jefferson University. Female SCID mice were obtained from the National Cancer Institute (Fredrick, MD). The compounds used in this study and their doses are as shown in Figure 5A . See supplementary section for details.
Results
VN/12-1 inhibits the growth of Breast Cancer Cell Lines
To determine if VN/12-1 exerts a growth inhibitory effect, MCF10A, MCF-7, SKBR-3 and MDA-MB-231 cells were treated with VN/12-1 and cell viability was analyzed using MTT assay ( Figure 1B; Supplementary Table S1 ). VN/12-1 did not induce any significant growth inhibitory effects in immortalized non-cancerous MCF10A cell line. However, it was quite potent against the cancer cell lines with IC 50 in the low µM range. Clinically used anti-cancer drugs ATRA, 4-hydroxytamoxifen (4-OHT) and letrozole also effectively inhibited the growth of MCF-7 cells (Supplementary Table S1 ). However, their potencies were significantly less than that of VN/12-1 against SKBR-3 and MDA-MB-231 cells.
Short exposure of VN/12-1 to breast cancer cells does not reduce cell viability
Cancer cells have fundamental differences in their metabolism and sensitivity to preconditioning, autophagy and apoptosis, so the dosage and duration of treatment with the therapeutic agents is important. Typically, short incubation time of treatment induces a protective mechanism by way of autophagy (25) . To test this, MCF-7, SKBR-3 and MDA-MB-231 cells were treated with 10 μM VN/12-1 and the compound was washed away at various time points (see Figure 1C) . The cells were then maintained in regular growth media until the endpoint of the MTT assay. As shown in Figure 1C , continuous exposure to VN/12-1 for at least [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] hours was needed to reduce the cell viability by ~20% for all the cells tested (p < 0.05). This indicates that the induction of growth inhibitory effect of VN/12-1 is time dependent.
Collectively, these data also suggest that the cells treated with VN/12-1 for a shorter time ( 
VN/12-1 induces autophagy and inhibits G1-S phase transition
Autophagy represents a failed attempt to adapt to stress and survival (31) . ER stress can also trigger autophagy (16, 17) (Figure 3C (a) and 3C (b) ). We also found that VN/12-1, combined with either CHL (Supplementary Figure 2D) 
Genomic silencing of Beclin-1 enhances the growth inhibitory activity of VN/12-1
To determine if autophagy inhibition by way of silencing an important autophagy geneBeclin-1 enhances the anti-cancer activity of VN/12-1, si-RNA technology was used. For Beclin-1, the si-RNA sequence that showed 90-100 % knockdown of the protein was selected for the studies (Supplementary Figure S2F) . As expected, SKBR-3 cells treated with VN/12-1 alone showed a decrease in viability by the MTT assay when compared to the vehicle treated (no si-RNA) and scrambled sequence si-RNA (scrambled-si-RNA) controls (p < 0.05) (Figure 3D ).
Cells treated with scrambled-siRNA plus VN/12-1 showed no change in activity compared to VN/12-1 alone (p>0.05). In the absence of VN/12-1, siRNA targeting Beclin-1 exerted little effects on SKBR-3 cell viability (p>0.05), but the combination of VN/12-1 with si-RNA for Beclin-1 resulted in a dramatic reduction in cell viability (p< 0.0005) (Figure 3D ).
VN/12-1 induces caspase-dependent apoptosis
Literature evidence suggests that the compounds that are autophagy inducers at smaller dose can induce apoptosis at higher dose (9) . In many situations, autophagy accompanies rather than causes apoptosis. Immnublots were done to determine whether VN/12-1 has apoptotic activity. The hallmarks of apoptosis, PARP cleavage and an upregulation of pro-apoptotic protein Bad were evident when VN/12-1 was combined with CHL ( Figure 4A 
Preliminary toxicology and pharmacokinetics (PK) of VN/12-1 in SCID mice
Prior to assessment of the in vivo anti-tumor efficacy of VN/12-1, we conducted preliminary toxicity and PK studies. Preliminary toxicity studies in SCID mice showed that VN/12-1 was not toxic as a single agent or in combination with CHL in the subcutaneous (s.c.) doses 2.5 and 5 mg/kg twice a week. In addition, preliminary pharmacokinetics following administration (s.c) of of 20 mg/kg of VN/12-1 showed that the peak plasma level after was 41.38 μg/ml and the mean t 1/2 was 6 hours. Details of these studies will be reported in a future manuscript.
VN/12-1 inhibits the growth of SKBR-3 xenografts
We evaluated VN/12-1's ability to inhibit the growth of SKBR-3 xenografts when given via s.c. administration. Mice were divided into 8 groups as detailed in the methods section. As shown in (Figure 5A (a) and 5A (b) ). Geometric means of starting tumor sizes were comparable across the 8 groups and ranged from 208 to 266 mm Representative pictures of tumors from each group are shown in Figure 5B . Figures 5C   (a) and 5C (b) show the average tumor weights and the body weights of the mice in different groups respectively. As shown in Figure 5C (a) , tumors in treatment groups involving the combination of VN/12-1 (either dose, 2.5 mg/kg and 5 mg/kg twice a week) and CHL had statistically significant reduction of tumor weights (p < 0.05 and p < 0.01 respectively).
However, there was no significant change in body weights of mice in any group.
In summary, the growth of tumors were significantly inhibited by all treatments ( Figures   5A (a) and 5A (b) ), but treatments with VN/12-1 (5 mg/kg) alone and its combination with CHL were the most effective, with impressive inhibitory values of 81.4% (p < 0.001 vs. control) and 96.2% (p < 0.001 vs. control), respectively without causing any toxicity.
Effect of VN/12-1 treatment on SKBR-3 tumor protein expressions
Immunoblot analysis of the tumor lysates confirmed the activation of autophagic pathway as there was a rise in LC3B expression in the VN/12-1 treatment groups but not in the ATRA group. As in the in vitro results, addition of CHL enhanced VN/12-1 upregulation of LC3B.
PARP cleavage and upregulation of pro-apoptotic Bad was noted in all the treated groups (except CHL group), more so in VN/12-1 and CHL combination groups ( Figure 5D) . Thus, these data identify apoptosis induction as a major mechanism underlying the ability of CHL to potentiate 
family inhibitors in combination with autophagy inhibitors (43) . Indeed, a number of clinical trials have been initiated in patients with solid and hematopoietic tumors to test the overall hypothesis that autophagy is a mechanism of therapeutic resistance (2).
Overall, following treatment of SKBR-3 cells with VN/12-1, our findings clearly demonstrate that VN/12-1 has dual effects (autophagy and apoptosis) based on the dose and duration of treatment. We also show that: (1) autophagy acts as a protective mechanism in SKBR-3 cells; (2) inhibition of autophagy can be exploited to potentiate VN/12-1-induced cell death, and (3) the combination of VN/12-1 with autophagy inhibitor(s) can reduce the dose of VN/12-1 and thus reduce its toxicity (if any). As with our other lead RAMBAs, the exact molecular targets (except CYP26) of VN/12-1 are yet to be identified. We envision that this will be achieved with ongoing studies directed at design and synthesis of appropriate biotinRAMBAs conjugates (molecular probes that retain potency in bioassays) (44) .
In summary, this study provides the first evidence that a RAMBA rapidly activates autophagy in breast cancer cells and that induction of autophagy by VN/12-1 can be exploited as a target to achieve enhanced anti-tumor efficacy. We suggest that VN/12-1 or the combination therapy of VN/12-1 and CHL is a potential strategy for the treatment of patients with breast cancer.
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